MiNK Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
15
- Stock Symbol
-
INKT
- Share Price
-
$9.53
- (As of Thursday Closing)
MiNK Therapeutics General Information
Description
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Contact Information
Website
www.minktherapeutics.comCorporate Office
- 149 Fifth Avenue
- Suite 500
- New York, NY 10010
- United States
Corporate Office
- 149 Fifth Avenue
- Suite 500
- New York, NY 10010
- United States
MiNK Therapeutics Stock Performance
As of 12-Nov-2026, MiNK Therapeutics’s stock price is $9.53. Its current market cap is $48.9M with 5.13M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.53 | $10.22 | $8.48 - $16.93 | $48.9M | 5.13M | 14.5K | -$2.23 |
MiNK Therapeutics Financials Summary
As of 30-Sep-2026, MiNK Therapeutics has a trailing 12-month revenue of $200K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 55,236 | 43,784 | 25,902 | 30,537 |
| Revenue | 200 | 0 | 0 | 0 |
| EBITDA | (11,215) | (12,493) | (10,742) | (22,716) |
| Net Income | (11,025) | (12,494) | (10,785) | (22,458) |
| Total Assets | 8,243 | 14,239 | 5,721 | 4,552 |
| Total Debt | 0 | 5,179 | 4,925 | 0 |
MiNK Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
MiNK Therapeutics Comparisons
Industry
Financing
Details
MiNK Therapeutics Competitors (14)
One of MiNK Therapeutics’s 14 competitors is Glycostem Therapeutics, a Private Equity-Backed company based in Oss, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Glycostem Therapeutics | Private Equity-Backed | Oss, Netherlands | ||||
| Arovella Therapeutics | Corporation | Preston, Australia | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA |
MiNK Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
MiNK Therapeutics Patents
MiNK Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025212740-A1 | Composition and methods for treating colorectal cancer liver metastasis (crc liver mets) | Pending | 03-Apr-2024 | ||
| EP-4801521-A1 | Allogeneic invariant natural killer t cells adjuvant for treatment of disease and related methods | Pending | 03-Nov-2023 | ||
| WO-2025097052-A1 | Allogeneic invariant natural killer t cells adjuvant for treatment of disease and related methods | Inactive | 03-Nov-2023 | ||
| WO-2025097052-A8 | Allogeneic invariant natural killer t cells adjuvant for treatment of disease and related methods | Inactive | 03-Nov-2023 | ||
| EP-4788350-A1 | Novel invariant natural killer t cells and t cell engager compositions and methods of use thereof | Pending | 05-Oct-2023 | A61P35/00 |
MiNK Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
MiNK Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
MiNK Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
32.76 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
MiNK Therapeutics FAQs
-
When was MiNK Therapeutics founded?
MiNK Therapeutics was founded in 2017.
-
Where is MiNK Therapeutics headquartered?
MiNK Therapeutics is headquartered in New York, NY.
-
What is the size of MiNK Therapeutics?
MiNK Therapeutics has 15 total employees.
-
What industry is MiNK Therapeutics in?
MiNK Therapeutics’s primary industry is Biotechnology.
-
Is MiNK Therapeutics a private or public company?
MiNK Therapeutics is a Public company.
-
What is MiNK Therapeutics’s stock symbol?
The ticker symbol for MiNK Therapeutics is INKT.
-
What is the current stock price of MiNK Therapeutics?
As of 12-Nov-2026 the stock price of MiNK Therapeutics is $9.53.
-
What is the current market cap of MiNK Therapeutics?
The current market capitalization of MiNK Therapeutics is $48.9M.
-
What is MiNK Therapeutics’s current revenue?
The trailing twelve month revenue for MiNK Therapeutics is $200K.
-
Who are MiNK Therapeutics’s competitors?
Glycostem Therapeutics, Arovella Therapeutics, Kite Pharma, Nkarta Therapeutics, and Poseida Therapeutics are some of the 14 competitors of MiNK Therapeutics.
-
What is MiNK Therapeutics’s annual earnings per share (EPS)?
MiNK Therapeutics’s EPS for 12 months was -$2.23.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
